Grown Rogue International (GRUSF) Amortizatization of Intangibles (2010 - 2026)
Grown Rogue International's (GRUSF) quarterly Amortizatization of Intangibles came in at $42210.0 in Q1 2026, down 80.83% year-on-year from $220133.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$812.2 billion in Q4 2025.
Grown Rogue International (GRUSF) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Grown Rogue International's Amortizatization of Intangibles history runs 11 years deep, the most recent figure standing at $42210.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 80.83% year-over-year to $42210.0 in Q1 2026; TTM through Mar 2026 was -$177923.0, a 110.62% decrease from a year earlier, with the FY2024 full-year figure at $1.8 million, up 748.27% from the prior year.
- Amortizatization of Intangibles advanced to $42210.0 in Q1 2026 per GRUSF's latest filing, from -$812.2 billion in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1531.6 billion in Q3 2024 and bottomed at -$1531.5 billion in Q4 2024.
- The 5-year median for Amortizatization of Intangibles is $294195.5 (2025), against an average of $263617.2.
- Across the five-year window, Amortizatization of Intangibles surged 46.97% in 2025 and tumbled 80.83% in 2026, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $151685.0 in 2022, then soared by 468.69% to $862624.0 in 2023, then tumbled by 177545492.15% to -$1531.5 billion in 2024, then jumped by 46.97% to -$812.2 billion in 2025, then soared by 100.0% to $42210.0 in 2026.
- Per Business Quant, the three latest GRUSF Amortizatization of Intangibles figures stand at $42210.0 (Q1 2026), -$812.2 billion (Q4 2025), and $812.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 86.26 Mn | 3.96 Mn | 42,210.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,210.00 |
| Mar 31, 2026 | 42,210.00 |
| Dec 31, 2025 | -812.21 Bn |
| Dec 31, 2025 | -812.21 Bn |
| Sep 30, 2025 | 812.21 Bn |
| Sep 30, 2025 | 812.21 Bn |
| Jun 30, 2025 | 368,258.00 |
| Jun 30, 2025 | 368,258.00 |
| Mar 31, 2025 | 220,133.00 |
| Mar 31, 2025 | 220,133.00 |
| Dec 31, 2024 | -1,531.55 Bn |
| Dec 31, 2024 | -1,531.55 Bn |
| Sep 30, 2024 | 1,531.55 Bn |
| Sep 30, 2024 | 1,531.55 Bn |
| Jun 30, 2024 | 378,404.00 |
| Jun 30, 2024 | 378,404.00 |
| Mar 31, 2024 | 381,663.00 |
| Mar 31, 2024 | 381,663.00 |
| Oct 31, 2023 | 862,624.00 |
| Oct 31, 2023 | 862,624.00 |